Derms on Drugs
Derms on Drugs
Podcast Description
Derms on Drugs is where cutting-edge dermatology meets mediocre comedy. Each week three dermatologists – Matt Zirwas, Laura Ferris and Tim Patton – discuss, debate, and dissect the hottest topics in dermatology.
It's everything you need to know to be on the cutting-edge of dermatology and it’ll be the most fun you’ve ever had while actually learning something useful.
Derms on Drugs is produced by Scholars in Medicine, an online educational platform (scholarsinmedicine.com) exclusively for healthcare professionals of all levels of experience and education.
Podcast Insights
Content Themes
The podcast focuses on a variety of dermatological topics, including drug comparisons, treatment efficacy, skin cancer implications, and patient mental health, with episode examples like 'Olumiant Showdown: Solo vs. Squad' and 'Melanoma's Mental Massacre'. Specific focus areas include updates on innovative treatments, discussions on side effects, and the impact of environmental factors on skin health.
Derms on Drugs is where cutting-edge dermatology meets mediocre comedy. Each week three dermatologists – Matt Zirwas, Laura Ferris and Tim Patton – discuss, debate, and dissect the hottest topics in dermatology.
It’s everything you need to know to be on the cutting-edge of dermatology and it’ll be the most fun you’ve ever had while actually learning something useful.
Derms on Drugs is produced by Scholars in Medicine, an online educational platform (scholarsinmedicine.com) exclusively for healthcare professionals of all levels of experience and education.
Ready to stay ahead in dermatology? Join the Derms on Drugs for a fast-paced, practical dive into the hottest new research and trends shaping our specialty.
This week, we break down:
Surprising long-term data comparing Dupixent and Rinvoq for atopic dermatitis
The future of autoimmune disease treatment: genetically modified T cells
What policies people actually support (and will pay for) to reduce skin cancer rates
JAK inhibitors for mucosal pemphigoid—what’s new, what works, and what to watch for
The latest on rising contact allergens: which ones are on the move and why
Packed with clinical pearls, practical tips, and a dash of humor, this episode is your shortcut to what’s new, what’s changing, and what you can use in practice right now.
Don’t miss out—hit play for your weekly dose of dermatology insights!
For links to all articles visit ScholarsinMedicine.com
1. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study
2. Janus Kinase Inhibitors in the Treatment of Refractory Cicatrizing Conjunctivitis in Pemphigoid
3. Long-Term Real-World Effectiveness of Dupilumab vs. Upadacitinib in early Treatment Responders with Atopic Dermatitis: Results from Central European Health Fund Registry
4. Mid-term effectiveness, safety, and potential predictors of response of upadacitinib in patients with moderate-to-severe atopic dermatitis: a multicenter observational retrospective study
5. Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents
6. Public preferences for skin cancer prevention policies: a discrete choice experiment in three European countries
7. North American Contact Dermatitis Group Patch Test Results: 2021–2022
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.